[HIV disease, antiretroviral treatment and the liver--emerging problems].
Both HIV disease and chronic HBV and HCV hepatitis recently benefited by significantly improved combination antiviral treatments, which, led to a remarkably increased life expectancy, and reduced morbidity and mortality rates of these potentially life-threatening disorders. However, many problems still wait definite solutions. Among them, the liver toxicity expected from administration of complex antiviral regimens (especially when co-infection is of concern), potential drug-drug interactions, the still unknown pathogenetic connections with the broad spectrum of metabolic abnormalities complicating long-term antiretroviral treatment, and the expected outcome of these issues on clinical management, therapeutic monitoring, and disease prognosis.
Manfredi
Roberto
R
Dipartimento di Medicina Clinica Specialistica e Sperimentale, Sezione di Malattie Infettive, Università degli Studi di Bologna Alma Mater Studiorum, Azienda Ospedaliera di Bologna, Policlinico S. Orsola-Malpighi, Bologna. manfredi@med.unibo.it
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000378:metabolism*; D008107:Liver Diseases / Q000150:complications* / Q000378:metabolism; D008930:Mitochondria, Liver / Q000187:drug effects / Q000378:metabolism; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors